OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RARE
Ultragenyx Pharmaceutical Inc.
There isn't enough reported data to score RARE yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RARE's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RARE PE Valuation
RARE has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 9.8x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RARE to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RARE on earnings quality, reporting a profit while its opponent remains loss making.
RARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.67 | — |
| Q3 2026 | -$5.18 | +$0.71 |
| Q2 2026 | -$5.83 | -$0.35 |
| Q1 2026 | -$6.10 | -$0.27 |
| Q4 2025 | -$5.83 | +$0.46 |
| Q3 2025 | -$5.89 | +$0.50 |
| Q2 2025 | -$5.48 | +$1.74 |
| Q1 2025 | -$5.83 | +$2.12 |
| Q4 2024 | -$6.29 | +$1.96 |
RARE is still losing money, but less than at its worst: $5.18 per share over the past year, against $10.26 at its worst in early 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RARE on profitability, with a higher operating margin.
RARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $173M | +8.2% |
| Q2 2026 | $214M | +29% |
| Q1 2026 | $136M | -2.4% |
| Q4 2025 | $207.3M | +26% |
| Q3 2025 | $159.9M | +15% |
| Q2 2025 | $166.5M | +13% |
| Q1 2025 | $139.3M | +28% |
| Q4 2024 | $164.9M | +29% |
RARE's revenue is growing: $173M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +43 points |
| Q2 2026 | -35% | +30 points |
| Q1 2026 | -124% | -22 points |
| Q4 2025 | -55% | +20 points |
| Q3 2025 | -107% | -12 points |
| Q2 2025 | -65% | +14 points |
| Q1 2025 | -103% | +49 points |
| Q4 2024 | -74% | +22 points |
RARE's operating margin was −64% last quarter, up 43 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
RARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45M | +$47.7M |
| Q2 2026 | -$98M | +$12.7M |
| Q1 2026 | -$198M | -$30.2M |
| Q4 2025 | -$100.8M | -$20.6M |
| Q3 2025 | -$92.7M | -$24.1M |
| Q2 2025 | -$110.7M | -$31.8M |
| Q1 2025 | -$167.8M | +$26.1M |
| Q4 2024 | -$80.2M | +$5.3M |
RARE has burned cash in almost every quarter: −$442M over the past year, against −$451M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +200K shares |
| 1 year | +2.3% | +2.3M shares |
| 3 years | +42% | +30.4M shares |
| 5 years | +50% | +34.2M shares |
| Available history | +80% | +45.5M shares |
RARE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RARE Net Leverage
RARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 20.3 | Neutral |
RARE's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RARE PE vs Healthcare Sector
RARE has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RARE on trend strength, trading above more of its moving averages.
RARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 5.6% above |
| 20 week MA | $21.0 | 22% below |
| 50 week MA | $23.4 | 31% below |
| 100 week MA | $29.5 | 45% below |
| 200 week MA | $37.2 | 56% below |
RARE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 56% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RARE on returns for 2026, with the stronger performance.
RARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $172.9 | +298% |
| 2021 | $172.9 | $84.7 | -51% |
| 2022 | $84.7 | $43.5 | -49% |
| 2023 | $43.5 | $47.8 | +9.9% |
| 2024 | $47.8 | $43.4 | -9.2% |
| 2025 | $43.4 | $34.2 | -21% |
| 2026 YTD | $34.2 | $16.3 | -52% |
RARE's yearly returns have swung widely, from +298% in 2020 to −51% in 2021. It's down 52% so far in 2026.